QLOSI (pilocarpine hydrochloride) by Orasis Pharmaceuticals is clinical pharmacology: pharmacodynamics: pilocarpine is a cholinergic parasympathomimetic agent exerting a broad spectrum of pharmacologic effects with predominant muscarinic action. First approved in 2023.
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
QLOSI (pilocarpine hydrochloride) is a cholinergic parasympathomimetic agent administered as an ophthalmic solution that stimulates muscarinic receptors to increase secretion from exocrine glands, particularly salivary flow. It is indicated for xerophthalmia and dry eye conditions in patients with head & neck cancer or Sjögren's syndrome. The drug works by enhancing glandular secretion and can cause miosis, accommodation spasm, and transient intraocular pressure changes followed by sustained reduction.
Early-stage commercial growth phase with small initial market penetration; brand team building phase likely focused on awareness and specialist engagement.
CLINICAL PHARMACOLOGY: Pharmacodynamics: Pilocarpine is a cholinergic parasympathomimetic agent exerting a broad spectrum of pharmacologic effects with predominant muscarinic action. Pilocarpine, in appropriate dosage, can increase secretion by the exocrine glands. The sweat, salivary, lacrimal,…
Worked on QLOSI at Orasis Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moQLOSI represents a specialist-focused, early-commercial opportunity in a niche ophthalmic therapeutic area with limited competition and an 11-year patent runway. Careers on this product offer targeted growth potential in a defined market segment with stable intellectual property protection and moderate team expansion expectations.